ONCO

DEF 14A - Onconetix, Inc. (0001782107) (Filer)

NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (NASDAQ:GRML), a critical and precious minerals development company. Additionally, the Company has added an investment in Onconetix Inc. (NASDAQ:ONCO). Onconetix has previously announced an agreement to acquire Realbotix LLC. Realbotix ut

PRE 14A - Onconetix, Inc. (0001782107) (Filer)

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today announced that it has provided a strategic bridge financing facility of up to $5,000,000 to Realbotix LLC ("Realbotix"), the target of its previously announced pending acquisition, to support Realbotix's growth and working capital needs while the parties advance toward closing of the acquisition. The financing was provided in connection with the Share Exchange Agreement

DEFA14A - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

425 - Onconetix, Inc. (0001782107) (Subject)

424B3 - Onconetix, Inc. (0001782107) (Filer)

EFFECT - Onconetix, Inc. (0001782107) (Filer)

425 - Onconetix, Inc. (0001782107) (Subject)

Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; Onconetix Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has announced a pilot program with a leading European telecommunications company

S-1/A - Onconetix, Inc. (0001782107) (Filer)

10-Q - Onconetix, Inc. (0001782107) (Filer)

S-1 - Onconetix, Inc. (0001782107) (Filer)

Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company"), a leader in humanoid robotics and embodied AI, reports its interim financial results for the three and nine months ended June 30, 2026 ("Q3-2026"). All dollar figures are reported in United States dollars ("USD"), unless otherwise stated. Realbotix Corp. is a holding company with two independently operated subsidiaries, Realbotix LLC and Intima LLC. While both leverage embedded AI and robotics, they offer distinct end products to different customer bases. Each maintains its own management, personnel, payroll, facilities, manufacturing operations, product development, and go-to-market strategies.

425 - Onconetix, Inc. (0001782107) (Subject)

Entertainment Industry Agreement Reflects Real-World Adoption of Humanoid Robotics Technology Across Education, Healthcare, Hospitality, and Customer Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has entered into an agreement with a recognized streaming platform to feature one of its humanoid robots as a

Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company’s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today announced that its fully-owned Swiss subsidiary, Proteomedix AG ("PMX"), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board. Dr. Schiess is a co-founder of Proteomedix AG and co-developer of Proclarix®, th

8-K - Onconetix, Inc. (0001782107) (Filer)

Commercial robotics and online consumer businesses maintain separate management, personnel, operations and product strategies Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company") provides an overview of its corporate and operating structure. Realbotix Corp. is a holding company with two separately operated businesses: Realbotix LLC, which focuses on AI-powered humanoid robotics for commercial service sector applications, and Intima LLC, which focuses on direct-to-consumer products. Realbotix LLC and Intima LLC have different product offerings with no crossover. As a holding company, Realbotix Corp. does not in itself have business operations but is

425 - Onconetix, Inc. (0001782107) (Subject)

Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom’s Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has announced a partnership with Bloom Procu

425 - Onconetix, Inc. (0001782107) (Subject)

Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, June 24, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has launched Optio, its AI-powered teacher’s assistant, in a pilot program a

424B3 - Onconetix, Inc. (0001782107) (Filer)